cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2020-35-1-13-21cardiotomsk-908Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНарушения ритма и проводимости сердца как проявления кардиотоксичности противоопухолевого лечения – миф или реальность?Heart rhythm and conduction disorders as manifestations of cardiotoxicity of anticancer treatment: myth or reality?https://orcid.org/0000-0003-2913-9797ВасюкЮ. А.VasyukYu. A.

20/1, Delegatskaya str., Moscow, 117473, Russian Federation

yvasyuk@yandex.ruhttps://orcid.org/0000-0001-6188-4610ШупенинаЕ. Ю.ShupeninaE. Y.

Cand. Sci. (Med.), Assistant Professor, Department of Clinical Functional Diagnostics

20/1, Delegatskaya str., Moscow, 117473, Russian Federation

eshupenina@mail.ruhttps://orcid.org/0000-0002-9873-8665НовоселЕ. О.NovoselE. O.

Medical Resident, Department of Hospital Therapy No. 1

20/1, Delegatskaya str., Moscow, 117473, Russian Federation

evgeniya.sechko@mail.ruhttps://orcid.org/0000-0001-7143-2087АгаповИ. С.AgapovI. S.

Medical Resident, Department of Hospital Therapy No. 1

20/1, Delegatskaya str., Moscow, 117473, Russian Federation

vanyok.agapov@gmail.comМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian Federation2020090420203511321Copyright © Васюк Ю.А., Шупенина Е.Ю., Новосел Е.О., Агапов И.С., 20202020Васюк Ю.А., Шупенина Е.Ю., Новосел Е.О., Агапов И.С.Vasyuk Y.A., Shupenina E.Y., Novosel E.O., Agapov I.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/908кардиотоксичностьфибрилляция предсердийсиндром удлиненного интервала QTантрациклинымоноклональные антителаингибиторы тирозинкиназcardiotoxicityatrial fibrillationQT prolongation syndromeanthracyclinesmonoclonal antibodiestyrosine kinase inhibitorsReferencesВасюк Ю.А., Ющук Е.Н., Несветов В.В. Кардиоонкология: новый вызов нашего времени. Сердечно-сосудистые осложнения противоопухолевого лечения. М.: Клинмедконсалтинг; 2019:100.Vasyuk Y.A., Yushchuk E.N., Nesvetov V.V. Cardiooncology: a new challenge of our time. Cardiovascular complications of antitumor treatment. Moscow: KlinmedConsulting; 2019:100 (In Russ.).Zamorano J., Lancellotti P., Munoz D., Aboyans V., Asteggiano R., Galderisi M. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 2016;37(36):2768–2801. DOI: 10.1093/eurheartj/ehw211.Zamorano J., Lancellotti P., Munoz D., Aboyans V., Asteggiano R., Galderisi M. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 2016;37(36):2768–2801. DOI: 10.1093/eurheartj/ehw211.Todaro M., Oreto L., Qamar R., Paterick T., Carerj S., Khandheria B. Cardioncology: state of the heart. Int. J. Cardiol. 2013;168:680–687.Todaro M., Oreto L., Qamar R., Paterick T., Carerj S., Khandheria B. Cardioncology: state of the heart. Int. J. Cardiol. 2013;168:680–687.Bhave M., Akhter N., Rosen S. Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park). 2014;28(6):482–490.Bhave M., Akhter N., Rosen S. Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park). 2014;28(6):482–490.Bowles E., Wellman R., Feigelson H., Onitilo A., Freedman A., Delate T. et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl. Cancer Inst. 2012;104(17):1293–1305. DOI: 10.1093/jnci/djs317.Bowles E., Wellman R., Feigelson H., Onitilo A., Freedman A., Delate T. et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl. Cancer Inst. 2012;104(17):1293–1305. DOI: 10.1093/jnci/djs317.Yang X., Li X., Yuan M., Tian C., Yang Y., Wang X. et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front. Pharmacol. 2018;9:1058. DOI: 10.3389/fphar.2018.01058.Yang X., Li X., Yuan M., Tian C., Yang Y., Wang X. et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front. Pharmacol. 2018;9:1058. DOI: 10.3389/fphar.2018.01058.Varga Z.V., Ferdinandy P., Liaudet L., Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am. J. Phys. Heart Circ. Phys. 2015;309(9):1453–1467. DOI: 10.1152/ajpheart.00554.2015.Varga Z.V., Ferdinandy P., Liaudet L., Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am. J. Phys. Heart Circ. Phys. 2015;309(9):1453–1467. DOI: 10.1152/ajpheart.00554.2015.Liu Y., Tan D., Shi L., Liu X., Zhang Y., Tong C. et al. Blueberry anthocyanins enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS One. 2015;10(7):e0127813. DOI: 10.1371/journal.pone.0127813.Liu Y., Tan D., Shi L., Liu X., Zhang Y., Tong C. et al. Blueberry anthocyanins enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS One. 2015;10(7):e0127813. DOI: 10.1371/journal.pone.0127813.Martinello R., Becco P., Vici P., Airoldi M., Del Mastro L., Garrone O. et al. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. Breast J. 2019;25(3):444–449. DOI: 10.1111/tbj.13240.Martinello R., Becco P., Vici P., Airoldi M., Del Mastro L., Garrone O. et al. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. Breast J. 2019;25(3):444–449. DOI: 10.1111/tbj.13240.Yuan M., Tse G., Zhang Z., Han X., Wu W.K.K., Li G. et al. The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis. Cardiovasc. Ther. 2018;36(6):e12475. DOI: 10.1111/1755-5922.12475.Yuan M., Tse G., Zhang Z., Han X., Wu W.K.K., Li G. et al. The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis. Cardiovasc. Ther. 2018;36(6):e12475. DOI: 10.1111/1755-5922.12475.Wang S.Y., Long J.B., Hurria A., Owusu C., Steingart R.M., Gross C.P. et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res. Treat. 2014;146(2):411–419. DOI: 10.1007/s10549-014-3029-0.Wang S.Y., Long J.B., Hurria A., Owusu C., Steingart R.M., Gross C.P. et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res. Treat. 2014;146(2):411–419. DOI: 10.1007/s10549-014-3029-0.Farmakis D., Parissis J., Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. JACC. 2014;63(10):945–953. DOI: 10.1016/j.jacc.2013.11.026.Farmakis D., Parissis J., Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. JACC. 2014;63(10):945–953. DOI: 10.1016/j.jacc.2013.11.026.Lenihan D.J., Kowey P.R. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18(8):900–908. DOI: 10.1634/theoncologist.2012-0466.Lenihan D.J., Kowey P.R. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18(8):900–908. DOI: 10.1634/theoncologist.2012-0466.Veronese P., Hachul D., Scanavacca M., Hajjar L., Wu T., Sacilotto L. et al. Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLoS One. 2018;13(5):e0196763. DOI: 10.1371/journal.pone.0196763.Veronese P., Hachul D., Scanavacca M., Hajjar L., Wu T., Sacilotto L. et al. Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLoS One. 2018;13(5):e0196763. DOI: 10.1371/journal.pone.0196763.Liu Y., Liu Y., Fan Z.W., Li J., Xu G.G. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur. J. Clin. Pharmacol. 2015;71(5):541–547. DOI: 10.1007/s00228-015-1831-1.Liu Y., Liu Y., Fan Z.W., Li J., Xu G.G. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur. J. Clin. Pharmacol. 2015;71(5):541–547. DOI: 10.1007/s00228-015-1831-1.Han J.Y., Lee S.H., Lee G.K., Yun T., Lee Y.J., Hwang K.H. et al. Phase I/II study of gefitinib (IressaR) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2015;75(3):475–483. DOI: 10.1007/s00280-014-2664-9.Han J.Y., Lee S.H., Lee G.K., Yun T., Lee Y.J., Hwang K.H. et al. Phase I/II study of gefitinib (IressaR) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2015;75(3):475–483. DOI: 10.1007/s00280-014-2664-9.O’Connor O.A., Horwitz S., Masszi T., Van Hoof A., Brown P., Doorduijn J. et al. Belinostat in patients with relapsed or refractoryperipheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study. J. Clin. Oncol. 2015;33(23):2492–2499. DOI: 10.1200/JCO.2014.59.2782.O’Connor O.A., Horwitz S., Masszi T., Van Hoof A., Brown P., Doorduijn J. et al. Belinostat in patients with relapsed or refractoryperipheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study. J. Clin. Oncol. 2015;33(23):2492–2499. DOI: 10.1200/JCO.2014.59.2782.Tisdale J. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can. Pharm. J. (Ott). 2016;149(3):139–152. DOI: 10.1177/1715163516641136.Tisdale J. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can. Pharm. J. (Ott). 2016;149(3):139–152. DOI: 10.1177/1715163516641136.Porta-Sanchez A., Gilbert C., Spears D., Amir E., Chan J., Nanthakumar K. et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J. Am. Heart Assoc. 2017;6(12):e07724. DOI: 10.1161/JAHA.117.007724.Porta-Sanchez A., Gilbert C., Spears D., Amir E., Chan J., Nanthakumar K. et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J. Am. Heart Assoc. 2017;6(12):e07724. DOI: 10.1161/JAHA.117.007724.Fradley M., Viganego F., Kip K., Martin A., Patel A., Ismail-Khan R. et al. Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart. 2017;4(2):e000701. DOI: 10.1136/openhrt-2017-000701.Fradley M., Viganego F., Kip K., Martin A., Patel A., Ismail-Khan R. et al. Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart. 2017;4(2):e000701. DOI: 10.1136/openhrt-2017-000701.Kilickap S., Barista I., Akgul E., Ytemir K., Aksoy S., Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. South. Med. J. 2007;100:262–265. DOI: 10.1097/01.smj.0000257382.89910.fe.Kilickap S., Barista I., Akgul E., Ytemir K., Aksoy S., Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. South. Med. J. 2007;100:262–265. DOI: 10.1097/01.smj.0000257382.89910.fe.Lynch D., Washam J., Newby L. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol. J. 2012;19(4):434–438.Lynch D., Washam J., Newby L. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol. J. 2012;19(4):434–438.Rowinsky E., Eisenhauer E., Chaudhry V., Arbuck S.G., Donehower R. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993;20(4):1–15.Rowinsky E., Eisenhauer E., Chaudhry V., Arbuck S.G., Donehower R. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993;20(4):1–15.Osman M., Elkady M. A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction. Breast Care. 2017;12(4):255–259. DOI: 10.1159/000471759.Osman M., Elkady M. A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction. Breast Care. 2017;12(4):255–259. DOI: 10.1159/000471759.Wheeler D., Liew T., Bailey A. Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel. Anaesthesia. 2007;62(2):186–189. DOI: 10.1111/j.1365-2044.2006.04946.x.Wheeler D., Liew T., Bailey A. Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel. Anaesthesia. 2007;62(2):186–189. DOI: 10.1111/j.1365-2044.2006.04946.x.Katsume Y., Isawa T., Toi Y., Fukuda R., Kondo Y., Sugawara S. et al. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern. Med. 2018;57(21):3157–3162. DOI: 10.2169/internalmedicine.0255-17.Katsume Y., Isawa T., Toi Y., Fukuda R., Kondo Y., Sugawara S. et al. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern. Med. 2018;57(21):3157–3162. DOI: 10.2169/internalmedicine.0255-17.Moses H., Matheson D.H., Cairns-Smith S., George B.P., Palisch C., Dorsey E.R. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189. DOI: 10.1001/jama.2014.15939.Moses H., Matheson D.H., Cairns-Smith S., George B.P., Palisch C., Dorsey E.R. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189. DOI: 10.1001/jama.2014.15939.Ferri N., Siegl P., Corsini A., Нerrmann J., Lerman A., Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol. Ther. 2013;138(3):470–484. DOI: 10.1016/j.pharmthera.2013.03.005.Ferri N., Siegl P., Corsini A., Нerrmann J., Lerman A., Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol. Ther. 2013;138(3):470–484. DOI: 10.1016/j.pharmthera.2013.03.005.Fleissig A.J.V., Jenkins V., Catt S., Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK. Lancet Oncol. 2006;7:935–943. DOI: 10.1016/S1470-2045(06)70940-8.Fleissig A.J.V., Jenkins V., Catt S., Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK. Lancet Oncol. 2006;7:935–943. DOI: 10.1016/S1470-2045(06)70940-8.

The authors declare that there are no conflicts of interest present.